Key Takeaways Alnylam's collaborations with Novartis, Roche, Sanofi, and Regeneron add to revenue growth.ALNY and Regeneron are advancing cemdisiran in phase III studies for multiple conditions.ALNY and Roche plan a global phase III ZENITH CV outcomes study of zilebesiran in hypertension patients.Alnylam Pharmaceuticals (ALNY) currently markets four approved drugs — Onpattro, Givlaari, Oxlumo, and Amvuttra — which together generated $1.14 billion in net product revenues, representing a 47% year-over-year in ...

Company Overview - Alnylam Pharmaceuticals, Inc. is a leading player in the biopharmaceutical industry, focusing on RNA interference (RNAi) therapeutics aimed at silencing specific genes associated with various diseases [1] - The company competes with other biotech firms such as Moderna and BioNTech, positioning itself among the leaders in the sector [1] Recent Developments - On September 5, 2025, Kostas Biliouris from BMO Capital set a price target of $470 for ALNY, indicating a potential upside of about 3.8% from its trading price of $452.81 at that time [2] - Alnylam participated in Citi's Biopharma Back to School Conference on September 3, 2025, where key executives discussed the company's strategic initiatives and future plans [3] Stock Performance - Currently, ALNY's stock is priced at $452.13, reflecting a slight decrease of 0.31% or $1.41, with a daily trading range between $444.66 and $455.05 [4] - Over the past year, ALNY has experienced significant volatility, with a high of $469.81 and a low of $205.87 [4] Market Position - Alnylam's market capitalization is approximately $59.26 billion, indicating a substantial presence in the market [5] - The stock has a trading volume of 264,290 shares on the NASDAQ exchange, highlighting active trading and investor interest in Alnylam's growth potential [5]

PresentationThank you all. Welcome all again to the 2025 Citi Biopharma Conference in Boston. Next on the docket, we have Alnylam. If you could, I guess, introduce us and kind of tell us a little bit about the company for no one who's -- for people who haven't heard of you before, bring us up to speed, that would be great.Jeffrey PoultonCFO & Executive VP [indiscernible] very productive organic platform for the company. We've got 6 products in the market today, 4 of which that we're marketing ourselves, whi ...

Alnylam Pharmaceuticals (ALNY) Conference September 03, 2025 01:45 PM ET Company ParticipantsJeff Poulton - CFOKevin Fitzgerald - Chief Scientific OfficerConference Call ParticipantsDavid Lebowitz - Senior Research Analyst - BiotechnologyDavid LebowitzThank you all. Welcome all again to the, twenty twenty five Citi Biopharma Conference in Boston. Next on the docket, we have Alnylam. If you could, I guess, introduce us and kind of tell us a little bit about the company for no one who's for people who haven't ...

Core Insights - Alnylam Pharmaceuticals is recognized as one of the leading biotech companies in the industry, demonstrating strong execution and performance [1] Company Performance - The company continues to achieve results that are well above average compared to its peers, reinforcing its position in the biotech sector [1]

Core Insights - Alnylam Pharmaceuticals and Roche reported positive mid-stage results for zilebesiran in patients with uncontrolled hypertension and high cardiovascular risk [1][5] Group 1: Study Results - The phase II KARDIA-3 study achieved its primary endpoint with a single 300 mg dose of zilebesiran showing placebo-adjusted reductions in office systolic blood pressure at month 3, although it did not meet the pre-specified statistical significance [3][5] - The 300 mg dose also resulted in clinically meaningful reductions in 24-hour mean ambulatory systolic blood pressure at three and six months, with effects sustained throughout the 24-hour cycle [3][6] - Zilebesiran demonstrated early and durable reductions in cardiovascular and renal biomarkers, indicating potential long-term benefits for high-risk populations [7] Group 2: Future Plans - Alnylam and Roche plan to initiate a global phase III cardiovascular outcomes trial, ZENITH, to evaluate zilebesiran's potential to reduce major adverse cardiovascular events [9][11] - The ZENITH study will enroll approximately 11,000 patients and is expected to start by late 2025, focusing on patients with uncontrolled hypertension on multiple antihypertensives [11] Group 3: Market Performance - Year to date, Alnylam's stock has increased by 89.8%, significantly outperforming the industry average growth of 2.7% [4]

Alnylam Pharmaceuticals (ALNY) Update / Briefing August 30, 2025 01:00 PM ET Company ParticipantsPushkal Garg - Executive VP, Chief Research & Development OfficerBryan Williams - Chair - Medicine & ProfessorNeha Pagidipati - Associate Professor of MedicineSimon Fox - VP - Zilebesiran Program LeadManu Chakravarthy - Senior VP, Global Head - Cardiovascular, Renal & Metabolism Product DevelopmentEllie Merle - Executive Director - Biotech Equity ResearchPushkal GargHello, everybody, and thank you for joining us ...

Core Viewpoint - Roche and Alnylam are initiating a Phase III cardiovascular outcomes trial (CVOT) for zilebesiran, an RNAi therapeutic aimed at reducing major adverse cardiovascular events in patients with uncontrolled hypertension [1][5]. Group 1: Clinical Trial Details - The Phase III trial, named ZENITH, will enroll approximately 11,000 patients and evaluate zilebesiran (300 mg) administered every six months compared to placebo [5][16]. - The KARDIA-3 study demonstrated a placebo-adjusted reduction in office systolic blood pressure (SBP) of -5.0 mmHg at month three and -3.9 mmHg at month six for the 300 mg dose [2][12]. - KARDIA-3 identified a patient population that could benefit most from zilebesiran, particularly those on diuretics with a baseline SBP greater than 140 mmHg, showing reductions of -9.2 mmHg at month three and -8.3 mmHg at month six [3][12]. Group 2: Safety and Efficacy - Zilebesiran exhibited an encouraging safety profile, with serious adverse events occurring in 3.8% of patients treated with zilebesiran compared to 4.5% in the placebo group, and no deaths reported during the six-month period [14]. - The drug demonstrated clinically meaningful reductions in blood pressure and sustained effects over six months, indicating its potential as a long-acting therapy for hypertension [8][12]. Group 3: Market Need and Potential - Hypertension affects over 1.2 billion people globally, with up to 80% of patients not achieving adequate blood pressure control, highlighting the need for new treatment options [6][20]. - Zilebesiran's biannual dosing could address adherence issues associated with daily oral therapies, potentially reducing the risk of serious health complications and cardiovascular events [4][17].

Key Takeaways Amvuttra drove $801.9 million in H1 2025 sales, up 89% year over year.U.S. and EU nods expanded Amvuttra's use to ATTR-CM, boosting uptake.Competition from Pfizer's Vyndaqel and BridgeBio's Attruby poses challenges.Alnylam Pharmaceuticals (ALNY) is a commercial-stage company that currently markets four drugs. The company first received regulatory approval in 2018 for Onpattro to treat adult patients with hereditary transthyretin-mediated (hATTR) amyloidosis. Subsequently, ALNY received approva ...

 Amsterdam, the Netherlands, August 26, 2025 – Scenic Biotech, a pioneer in modifier therapies for severe diseases, today announced a license and research agreement with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) to leverage Scenic's Cell-Seq platform for discovering novel targets for RNAi therapeutics. "Collaborating with the leading innovator in RNAi therapeutics represents significant validation of our Cell-Seq platform's unique ability to connect cellular pathways to actionable drug targets," said Vin ...